Recent guidelines demand referral to a tertiary or liver center in possible cases of intermediate-to-high risk for advanced fibrosis based on low cut-off values (COVs) of Fib-4 and/or NFS in patients with NAFLD [7,8]. This evidence concerns the gene FBL and metabolic dysfunction-associated steatotic liver disease.